(DVA) DaVita HealthCare Partners - Overview
Sector: HealthcareIndustry: Medical Care Facilities | Exchange NYSE (USA) | Currency USD | Market Cap: 10.175m | Total Return 3.6% in 12m
Stock: Kidney Dialysis, Lab Services, Integrated Care, Transplant Software
Total Rating 62
Risk 63
Buy Signal 0.66
| Risk 5d forecast | |
|---|---|
| Volatility | 31.0% |
| Relative Tail Risk | -9.37% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.15 |
| Alpha | -4.22 |
| Character TTM | |
|---|---|
| Beta | 0.431 |
| Beta Downside | 0.904 |
| Drawdowns 3y | |
|---|---|
| Max DD | 41.43% |
| CAGR/Max DD | 0.62 |
EPS (Earnings per Share)
Revenue
Description: DVA DaVita HealthCare Partners March 05, 2026
DaVita Inc. (DVA) is a U.S.-based healthcare services company specializing in kidney dialysis. The company operates outpatient and inpatient dialysis centers, offering hemodialysis and related laboratory services. DaVitas business model includes integrated care arrangements and clinical research, addressing the chronic nature of kidney failure.
The healthcare services sector, particularly dialysis, often involves long-term patient relationships due to the ongoing need for treatment. DaVita also provides management services for other dialysis centers and engages in transplant software. For more detailed analysis, consider exploring ValueRays comprehensive reports.
Headlines to watch out for
- ESRD patient growth drives dialysis service demand
- Government reimbursement rates impact revenue per treatment
- Labor costs and staffing shortages pressure margins
- Regulatory changes in healthcare policy create uncertainty
- Integrated kidney care models expand revenue opportunities
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income: 746.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA -0.99 > 1.0 |
| NWC/Revenue: 6.72% < 20% (prev 6.03%; Δ 0.69% < -1%) |
| CFO/TA 0.11 > 3% & CFO 1.89b > Net Income 746.8m |
| Net Debt (14.29b) to EBITDA (2.64b): 5.41 < 3 |
| Current Ratio: 1.29 > 1.5 & < 3 |
| Outstanding Shares: last quarter (88.1m) vs 12m ago 2.69% < -2% |
| Gross Margin: 30.88% > 18% (prev 0.33%; Δ 3.06k% > 0.5%) |
| Asset Turnover: 78.49% > 50% (prev 74.14%; Δ 4.35% > 0%) |
| Interest Coverage Ratio: 3.51 > 6 (EBITDA TTM 2.64b / Interest Expense TTM 549.7m) |
Altman Z'' 1.00
| A: 0.05 (Total Current Assets 4.06b - Total Current Liabilities 3.14b) / Total Assets 17.48b |
| B: -0.02 (Retained Earnings -328.4m / Total Assets 17.48b) |
| C: 0.11 (EBIT TTM 1.93b / Avg Total Assets 17.38b) |
| D: -0.03 (Book Value of Equity -451.1m / Total Liabilities 16.32b) |
| Altman-Z'' Score: 1.00 = BB |
Beneish M -2.88
| DSRI: 1.10 (Receivables 2.96b/2.53b, Revenue 13.64b/12.82b) |
| GMI: 1.07 (GM 30.88% / 32.91%) |
| AQI: 1.04 (AQ_t 0.47 / AQ_t-1 0.45) |
| SGI: 1.06 (Revenue 13.64b / 12.82b) |
| TATA: -0.07 (NI 746.8m - CFO 1.89b) / TA 17.48b) |
| Beneish M-Score: -2.88 (Cap -4..+1) = A |
What is the price of DVA shares?
As of March 27, 2026, the stock is trading at USD 156.76 with a total of 591,765 shares traded.
Over the past week, the price has changed by +4.67%, over one month by +2.77%, over three months by +37.53% and over the past year by +3.56%.
Over the past week, the price has changed by +4.67%, over one month by +2.77%, over three months by +37.53% and over the past year by +3.56%.
Is DVA a buy, sell or hold?
DaVita HealthCare Partners has received a consensus analysts rating of 3.10.
Therefor, it is recommend to hold DVA.
- StrongBuy: 1
- Buy: 0
- Hold: 8
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the DVA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 151.7 | -3.2% |
| Analysts Target Price | 151.7 | -3.2% |
DVA Fundamental Data Overview March 25, 2026
P/E Trailing = 16.0053
P/E Forward = 10.7875
P/S = 0.7458
P/B = 21.6266
P/EG = 0.555
Revenue TTM = 13.64b USD
EBIT TTM = 1.93b USD
EBITDA TTM = 2.64b USD
Long Term Debt = 10.16b USD (from longTermDebt, last quarter)
Short Term Debt = 534.7m USD (from shortTermDebt, last quarter)
Debt = 15.05b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 14.29b USD (from netDebt column, last quarter)
Enterprise Value = 24.55b USD (10.18b + Debt 15.05b - CCE 676.4m)
Interest Coverage Ratio = 3.51 (Ebit TTM 1.93b / Interest Expense TTM 549.7m)
EV/FCF = 18.73x (Enterprise Value 24.55b / FCF TTM 1.31b)
FCF Yield = 5.34% (FCF TTM 1.31b / Enterprise Value 24.55b)
FCF Margin = 9.61% (FCF TTM 1.31b / Revenue TTM 13.64b)
Net Margin = 5.47% (Net Income TTM 746.8m / Revenue TTM 13.64b)
Gross Margin = 30.88% ((Revenue TTM 13.64b - Cost of Revenue TTM 9.43b) / Revenue TTM)
Gross Margin QoQ = 28.28% (prev 31.80%)
Tobins Q-Ratio = 1.40 (Enterprise Value 24.55b / Total Assets 17.48b)
Interest Expense / Debt = 0.78% (Interest Expense 118.0m / Debt 15.05b)
Taxrate = 20.05% (76.7m / 382.8m)
NOPAT = 1.54b (EBIT 1.93b * (1 - 20.05%))
Current Ratio = 1.29 (Total Current Assets 4.06b / Total Current Liabilities 3.14b)
Debt / Equity = -23.12 (negative equity) (Debt 15.05b / totalStockholderEquity, last quarter -651.1m)
Debt / EBITDA = 5.41 (Net Debt 14.29b / EBITDA 2.64b)
Debt / FCF = 10.90 (Net Debt 14.29b / FCF TTM 1.31b)
Total Stockholder Equity = -464.9m (last 4 quarters mean from totalStockholderEquity)
RoA = 4.30% (Net Income 746.8m / Total Assets 17.48b)
RoE = -160.6% (negative equity) (Net Income TTM 746.8m / Total Stockholder Equity -464.9m)
RoCE = 19.87% (EBIT 1.93b / Capital Employed (Equity -464.9m + L.T.Debt 10.16b))
RoIC = 15.94% (NOPAT 1.54b / Invested Capital 9.66b)
WACC = 3.40% (E(10.18b)/V(25.23b) * Re(7.50%) + D(15.05b)/V(25.23b) * Rd(0.78%) * (1-Tc(0.20)))
Discount Rate = 7.50% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares Correlation 3-Years: -33.33 | Cagr: -2.56%
[DCF] Terminal Value 86.37% ; FCFF base≈1.37b ; Y1≈1.38b ; Y5≈1.47b
[DCF] Fair Price = 440.4 (EV 43.73b - Net Debt 14.29b = Equity 29.44b / Shares 66.8m; r=6.0% [WACC]; 5y FCF grow -0.16% → 3.0% )
EPS Correlation: 63.88 | EPS CAGR: 22.06% | SUE: 1.02 | # QB: 1
Revenue Correlation: 95.69 | Revenue CAGR: 6.91% | SUE: 2.87 | # QB: 1
EPS next Quarter (2026-06-30): EPS=3.66 | Chg7d=-0.012 | Chg30d=+0.329 | Revisions Net=+3 | Analysts=6
EPS current Year (2026-12-31): EPS=14.08 | Chg7d=-0.036 | Chg30d=+1.328 | Revisions Net=+7 | Growth EPS=+30.6% | Growth Revenue=+3.0%
EPS next Year (2027-12-31): EPS=16.33 | Chg7d=+0.161 | Chg30d=+1.402 | Revisions Net=+6 | Growth EPS=+16.0% | Growth Revenue=+3.1%
[Analyst] Revisions Ratio: +1.00 (3 Up / 0 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 1.7% (Discount Rate 7.9% - Earnings Yield 6.2%)
[Growth] Growth Spread = +1.1% (Analyst 2.7% - Implied 1.7%)
P/E Forward = 10.7875
P/S = 0.7458
P/B = 21.6266
P/EG = 0.555
Revenue TTM = 13.64b USD
EBIT TTM = 1.93b USD
EBITDA TTM = 2.64b USD
Long Term Debt = 10.16b USD (from longTermDebt, last quarter)
Short Term Debt = 534.7m USD (from shortTermDebt, last quarter)
Debt = 15.05b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 14.29b USD (from netDebt column, last quarter)
Enterprise Value = 24.55b USD (10.18b + Debt 15.05b - CCE 676.4m)
Interest Coverage Ratio = 3.51 (Ebit TTM 1.93b / Interest Expense TTM 549.7m)
EV/FCF = 18.73x (Enterprise Value 24.55b / FCF TTM 1.31b)
FCF Yield = 5.34% (FCF TTM 1.31b / Enterprise Value 24.55b)
FCF Margin = 9.61% (FCF TTM 1.31b / Revenue TTM 13.64b)
Net Margin = 5.47% (Net Income TTM 746.8m / Revenue TTM 13.64b)
Gross Margin = 30.88% ((Revenue TTM 13.64b - Cost of Revenue TTM 9.43b) / Revenue TTM)
Gross Margin QoQ = 28.28% (prev 31.80%)
Tobins Q-Ratio = 1.40 (Enterprise Value 24.55b / Total Assets 17.48b)
Interest Expense / Debt = 0.78% (Interest Expense 118.0m / Debt 15.05b)
Taxrate = 20.05% (76.7m / 382.8m)
NOPAT = 1.54b (EBIT 1.93b * (1 - 20.05%))
Current Ratio = 1.29 (Total Current Assets 4.06b / Total Current Liabilities 3.14b)
Debt / Equity = -23.12 (negative equity) (Debt 15.05b / totalStockholderEquity, last quarter -651.1m)
Debt / EBITDA = 5.41 (Net Debt 14.29b / EBITDA 2.64b)
Debt / FCF = 10.90 (Net Debt 14.29b / FCF TTM 1.31b)
Total Stockholder Equity = -464.9m (last 4 quarters mean from totalStockholderEquity)
RoA = 4.30% (Net Income 746.8m / Total Assets 17.48b)
RoE = -160.6% (negative equity) (Net Income TTM 746.8m / Total Stockholder Equity -464.9m)
RoCE = 19.87% (EBIT 1.93b / Capital Employed (Equity -464.9m + L.T.Debt 10.16b))
RoIC = 15.94% (NOPAT 1.54b / Invested Capital 9.66b)
WACC = 3.40% (E(10.18b)/V(25.23b) * Re(7.50%) + D(15.05b)/V(25.23b) * Rd(0.78%) * (1-Tc(0.20)))
Discount Rate = 7.50% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares Correlation 3-Years: -33.33 | Cagr: -2.56%
[DCF] Terminal Value 86.37% ; FCFF base≈1.37b ; Y1≈1.38b ; Y5≈1.47b
[DCF] Fair Price = 440.4 (EV 43.73b - Net Debt 14.29b = Equity 29.44b / Shares 66.8m; r=6.0% [WACC]; 5y FCF grow -0.16% → 3.0% )
EPS Correlation: 63.88 | EPS CAGR: 22.06% | SUE: 1.02 | # QB: 1
Revenue Correlation: 95.69 | Revenue CAGR: 6.91% | SUE: 2.87 | # QB: 1
EPS next Quarter (2026-06-30): EPS=3.66 | Chg7d=-0.012 | Chg30d=+0.329 | Revisions Net=+3 | Analysts=6
EPS current Year (2026-12-31): EPS=14.08 | Chg7d=-0.036 | Chg30d=+1.328 | Revisions Net=+7 | Growth EPS=+30.6% | Growth Revenue=+3.0%
EPS next Year (2027-12-31): EPS=16.33 | Chg7d=+0.161 | Chg30d=+1.402 | Revisions Net=+6 | Growth EPS=+16.0% | Growth Revenue=+3.1%
[Analyst] Revisions Ratio: +1.00 (3 Up / 0 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 1.7% (Discount Rate 7.9% - Earnings Yield 6.2%)
[Growth] Growth Spread = +1.1% (Analyst 2.7% - Implied 1.7%)